Phreesia, Inc. (NYSE:PHR – Get Free Report) CFO Balaji Gandhi sold 4,813 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $27.48, for a total value of $132,261.24. Following the completion of the sale, the chief financial officer now directly owns 144,933 shares in the company, valued at $3,982,758.84. This trade represents a 3.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Balaji Gandhi also recently made the following trade(s):
- On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total transaction of $159,135.37.
- On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total transaction of $22,555.28.
- On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total transaction of $85,018.95.
Phreesia Trading Up 1.1 %
NYSE:PHR opened at $29.03 on Friday. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.90. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The firm’s fifty day moving average is $24.78 and its 200-day moving average is $23.24. The firm has a market cap of $1.69 billion, a P/E ratio of -19.75 and a beta of 0.94.
Analysts Set New Price Targets
PHR has been the subject of several research analyst reports. JMP Securities reiterated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Friday, January 10th. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Piper Sandler restated an “overweight” rating and set a $33.00 price target (up from $31.00) on shares of Phreesia in a report on Wednesday. Finally, Citigroup raised their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. Thirteen investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $31.15.
View Our Latest Stock Report on PHR
Institutional Investors Weigh In On Phreesia
Several large investors have recently added to or reduced their stakes in PHR. Champlain Investment Partners LLC lifted its stake in Phreesia by 4.1% in the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after buying an additional 97,847 shares during the period. Sei Investments Co. increased its stake in shares of Phreesia by 135.3% in the 2nd quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock valued at $3,505,000 after acquiring an additional 95,058 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of Phreesia by 56.3% during the 2nd quarter. Squarepoint Ops LLC now owns 250,396 shares of the company’s stock valued at $5,308,000 after acquiring an additional 90,215 shares during the period. State Street Corp boosted its stake in Phreesia by 7.1% during the third quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after acquiring an additional 88,517 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Phreesia by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock worth $28,397,000 after purchasing an additional 55,934 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Stories
- Five stocks we like better than Phreesia
- 3 Ways To Invest In Coffee, Other Than Drinking It
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- How is Compound Interest Calculated?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- What Are Dividend Champions? How to Invest in the Champions
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.